about
A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheresImaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.Mycobacterium mimicking metastatic melanoma.Interventional therapies for malignant pleural effusions: the present and the future.(68) Ga-somatostatin analogue PET-CT: Analysis of costs and benefits in a public hospital setting.The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study.A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment.Is FCH PET able to identify foci of infection superiorly to FDG PET?A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.A gelatin liver phantom of suspended 90Y resin microspheres to simulate the physiologic microsphere biodistribution of a postradioembolization liver.Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions.Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.In search of the vulnerable patient or the vulnerable plaque: F-sodium fluoride positron emission tomography for cardiovascular risk stratificationA Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural MesotheliomaA prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial prTheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)3-year freedom from progression following 68GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trialComparison between gallium-68 citrate positron emission tomography-computed tomography and gallium-67 citrate scintigraphy for infection imagingCoronary artery 18F-NaF PET analysis with the use of an elastic motion correction softwareImaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest GroupA Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard ImagingBaseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional TherapyRadiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesoth
P50
Q33387524-AAD49A5E-6C76-4654-A4BD-542B2CA7EF95Q37071558-EA30C0BC-7AE8-43F4-9631-225992695A34Q37764507-366C9A13-46DD-410D-9AD4-9832D2251B1AQ38170567-064EB5E8-6648-410C-BBCF-F15094CB9628Q38221769-EF7DFDA6-A58A-442D-8DEC-9B78FBB83674Q38676211-DCEC977C-3A65-467A-988A-583771D8B28BQ38711300-FA93FF91-674A-41BD-A823-EC99526D9361Q38828734-515F2A7D-0B07-4EA9-B529-0DD0EF893581Q40134079-B1BF2E1F-8F4D-4858-89BA-AA4EF9770679Q40522944-716356F4-76AE-45E7-A26C-448A8B39CF5BQ50709215-99879FB5-1C71-4968-9EBC-5218B6822F7BQ51526704-58B46EF9-ECCD-4C7D-A8F7-639F26184DD4Q51605299-E88CB1D6-FA75-4626-98D9-E2BE341E3949Q52983532-76F5233C-8EBD-40D3-95DB-E41ED94567D6Q53036861-BF452194-9F6B-4844-8131-5C06EAA87B61Q53054513-199D5D62-A571-48B8-B74A-55787316D820Q53128417-CE8C559E-9EE9-4B98-913F-4191B0DE3444Q53468208-5FD6B92F-21E5-439D-9959-BB96664A25A8Q57176632-2F7D2DED-FC70-48D5-BF3A-00B3890A3548Q61627994-514DC960-4A2A-43A3-A276-A119220FADB2Q88565499-2E8543F0-549F-4B23-A8F3-A71CF10510CFQ90869309-9744B987-A8A7-46C9-A427-3F6B40B67AB1Q91062309-8ED0DD8A-D717-433A-86C6-968B725C8DC7Q91153131-37665E3F-5866-461E-8E54-FCE0A2ACE8DDQ91230867-F1BD156C-ABD2-42BB-B702-FE1BBECF7068Q92454433-4B44238D-0ED9-4D09-9EF4-DA94D38E9950Q92486520-36AFB627-37E3-4CFB-957B-49F6182D49F9Q92805733-A78083C9-5698-4D5A-B582-CFEAE89F1F86Q93013647-A41EF6CC-65DA-4214-9E22-7B2A0E038732
P50
description
researcher, ORCID id # 0000-0002-6256-1351
@en
wetenschapper
@nl
name
Roslyn J Francis
@ast
Roslyn J Francis
@en
Roslyn J Francis
@es
Roslyn J Francis
@nl
type
label
Roslyn J Francis
@ast
Roslyn J Francis
@en
Roslyn J Francis
@es
Roslyn J Francis
@nl
prefLabel
Roslyn J Francis
@ast
Roslyn J Francis
@en
Roslyn J Francis
@es
Roslyn J Francis
@nl
P106
P1153
7202122104
P31
P496
0000-0002-6256-1351